此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis

2026年7月13日 更新者:Peter Caravan

Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Lung Fibrosis in Participants With Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease

The purpose of this study is to investigate how immunosuppression treatment affects measurements of active collagen deposition using [68Ga]CBP8 positron emission tomography (PET) and tissue injury using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in individuals with non-idiopathic pulmonary fibrosis interstitial lung disease (non-IPF ILD).

研究概览

详细说明

15 different subjects with non-IPF ILD starting immunosuppression treatment for their underlying ILD will be enrolled. Participants will undergo [68Ga]CBP8 PET and DCE-MRI prior to and 12 weeks after treatment initiation to determine the effects of immunosuppressive treatment on PET measurements of collagen deposition and selected DCE-MRI-derived measurements.

研究类型

介入性

注册 (估计的)

15

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • 招聘中
        • Massachusetts General Hospital
        • 首席研究员:
          • Sydney Montesi, MD
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  1. Age 18-80 with a diagnosis of chronic hypersensitivity pneumonitis, connective tissue-associated ILD (due to rheumatoid arthritis, systemic sclerosis, mixed connective tissue disease), or undifferentiated ILD.
  2. Starting immunosuppression treatment with mycophenolate mofetil, mycophenolate sodium, and / or prednisone for clinically indicated non-IPF ILD treatment.
  3. Pulmonary fibrosis, defined as honeycombing, traction bronchiectasis, or reticular opacities on high-resolution computed tomography (HRCT) performed within 1 year to or at Visit 1.
  4. Forced vital capacity (FVC) of >/= 45% and diffusing capacity of the lungs for carbon monoxide (DLCO) >/= 25% predicted on PFTs performed at Visit 1.

Exclusion criteria:

  1. Current or prior exposure to FDA approved anti-fibrotic therapy.
  2. Extent of emphysema greater than extent of fibrosis.
  3. Pregnancy or plans to become pregnant at baseline or during follow-up.
  4. Contraindications to MRI.
  5. Contraindications to receiving gadolinium-based contrast agents.
  6. Research-related radiation exposure exceeds 50 millisievert (mSv) in the prior year.
  7. Estimated glomerular filtration rate (eGFR) < 30 mL/min (only for individuals with a history of chronic kidney disease).
  8. Clinically significant pulmonary hypertension (PH) defined by use of pulmonary vasodilatory therapy.
  9. Respiratory infection within the prior 6 weeks.
  10. Smoking of any kind within the prior 6 months.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:诊断
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Participants with Pulmonary Fibrosis
Participants with non-idiopathic pulmonary fibrosis interstitial lung disease (non-IPF ILD) will receive [68Ga]CBP8 and undergo PET combined with dynamic contrast-enhanced MRI prior to and 12 weeks after starting clinically-prescribed immunosuppression for treatment of non-IPF ILD
参与者将接受单次静脉注射高达 350 MBq 的 [68Ga]CBP8
参与者将在 DCE-MRI 期间接受单次静脉注射 0.05 mmol/kg 钆酸葡甲胺

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in SUVmax25 over the entire lungs
大体时间:From baseline to 12 weeks
Changes in lung collagen uptake will be measured using the PET probe [68]Ga-CBP8. Measurements will be made using the mean of the upper quartile of standardized uptake values (SUVmax25). Primary [68Ga]CBP8-PET outcome.
From baseline to 12 weeks
Change in the rate of contrast washin (kwashin) over the entire lungs
大体时间:From baseline to 12 weeks
Changes in rate of contrast washin will be measured using dynamic-contrast enhanced MRI. Primary DCE-MRI outcomes.
From baseline to 12 weeks

次要结果测量

结果测量
措施说明
大体时间
Change in SUVmean over the entire lungs
大体时间:From baseline to 12 weeks
Changes in lung collagen uptake will be measured using the PET probe [68]Ga-CBP8. Measurements will be made using the mean standardized uptake value (SUVmean).
From baseline to 12 weeks
Change in SUVmax over the entire lungs
大体时间:From baseline to 12 weeks
Changes in lung collagen uptake will be measured using the PET probe [68]Ga-CBP8. Measurements will be made using the max standardized uptake value (SUVmax).
From baseline to 12 weeks
Change in peak enhancement over the entire lungs
大体时间:From baseline to 12 weeks
Changes in peak enhancement will be measured using dynamic-contrast enhanced MRI
From baseline to 12 weeks
Change in time to peak over the entire lungs
大体时间:From baseline to 12 weeks
Changes in time to peak will be measured using dynamic-contrast enhanced MRI
From baseline to 12 weeks
Change in the area under the curve at 60 seconds (AUC60) over the entire lungs
大体时间:From baseline to 12 weeks
Changes in the area under the curve at 60 seconds will be measured using dynamic-contrast enhanced MRI
From baseline to 12 weeks
Change in the rate of contrast washout (kwashout) over the entire lungs
大体时间:From baseline to 12 weeks
Changes in the rate of contrast washout will be measured using dynamic-contrast enhanced MRI.
From baseline to 12 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Sydney Montesi, MD、Massachusetts General Hospital

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年5月14日

初级完成 (估计的)

2028年12月31日

研究完成 (估计的)

2028年12月31日

研究注册日期

首次提交

2026年4月17日

首先提交符合 QC 标准的

2026年5月2日

首次发布 (实际的)

2026年5月7日

研究记录更新

最后更新发布 (实际的)

2026年7月14日

上次提交的符合 QC 标准的更新

2026年7月13日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

其他研究编号

  • 2024P001746Aim3
  • R01HL171240 (美国 NIH 拨款/合同)

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅